immunine 200 ui polvo y disolvente para solucion inyectable o para perfusion
baxter, s.l. - factor ix - excipientes: cloruro de sodio,citrato de sodio (e-331) - vitamina k y otros hemostÁticos - factores de la coagulación sanguínea - factor ix de la coagulacion
firialta comprimidos recubiertos 20 mg (finerenona)
bayer s.a. - finerenona - sin formulas
kineret
swedish orphan biovitrum ab (publ) - anakinra - arthritis, rheumatoid; covid-19 virus infection - inmunosupresores - la artritis reumatoide (ar)kineret está indicado en adultos para el tratamiento de los signos y síntomas de la ar en combinación con metotrexato, con una respuesta inadecuada a metotrexato solo. covid-19kineret is indicated for the treatment of coronavirus disease 2019 (covid-19) in adult patients with pneumonia requiring supplemental oxygen (low- or high-flow oxygen) who are at risk of progressing to severe respiratory failure determined by plasma concentration of soluble urokinase plasminogen activator receptor (supar) ≥ 6 ng/ml. periodic fever syndromeskineret is indicated for the treatment of the following autoinflammatory periodic fever syndromes in adults, adolescents, children and infants aged 8 months and older with a body weight of 10 kg or above:cryopyrin-associated periodic syndromes (caps)kineret is indicated for the treatment of caps, including:neonatal-onset multisystem inflammatory disease (nomid) / chronic infantile neurological, cutaneous, articular syndrome (cinca)muckle-wells syndrome (mws)familial cold autoinflammatory syndrome (fcas)familial mediterranean fever (fmf)kineret is indicated for the treatment of familial mediterranean fever (fmf). kineret debe administrarse en combinación con colchicina, si es apropiado. still’s diseasekineret is indicated in adults, adolescents, children and infants aged 8 months and older with a body weight of 10 kg or above for the treatment of still’s disease, including systemic juvenile idiopathic arthritis (sjia) and adult-onset still’s disease (aosd), with active systemic features of moderate to high disease activity, or in patients with continued disease activity after treatment with non-steroidal anti-inflammatory drugs (nsaids) or glucocorticoids. kineret can be given as monotherapy or in combination with other anti-inflammatory drugs and disease-modifying antirheumatic drugs (dmards).
inegy 10 mg/10 mg comprimidos
merck sharp and dohme sp ltd. - ezetimiba, simvastatina - excipientes: - agentes modificadores de los lÍpidos, combinaciones - inhibidores de la hmg-coa reductasa en combinación con otros agentes modificadores de lipidos -
inegy 10 mg/80 mg comprimidos
merck sharp and dohme sp ltd. - ezetimiba, simvastatina - excipientes: - agentes modificadores de los lÍpidos, combinaciones - inhibidores de la hmg-coa reductasa en combinación con otros agentes modificadores de lipidos -
navelbine 10 mg/ml concentrado para solucion para perfusion
pierre fabre iberica s.a. - vinorelbina - concentrado para soluciÓn para perfusiÓn - 10 mg/ml inyectable 5 ml - vinorelbina 10 mg - vinorelbina
navelbine 50 mg/5 ml concentrado para solucion para perfusion
pierre fabre iberica s.a. - vinorelbina - concentrado para soluciÓn para perfusiÓn - 10 mg/ml inyectable 5 ml - vinorelbina 10 mg - vinorelbina
octanine 100 ui/ml polvo y disolvente para solucion inyectable
octapharma s.a. - factor ix - polvo y disolvente para soluciÓn inyectable - 1.000 ui - factor ix 1000 ui - factor ix de la coagulacion